Evidence map›Paper›PMID 34286142›Full record

ArticleHeliyon2021

Synthesis, antibacterial, anti-oxidant and molecular docking studies of imidazoquinolines.

K Velmurugan, Derin Don, Rajesh Kannan, C Selvaraj, S VishnuPriya, G Selvaraj, S K Singh, R Nandhakumar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Synthesis of arylated tetrahydrobenzo[Future medicinal chemistry · 2024
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

K VelmuruganDepartment of Applied Chemistry, Karunya Institute of Technology and Sciences (Deemed-to-be University), Karunya Nagar, Coimbatore, 641 114, India.
Derin DonDepartment of Applied Chemistry, Karunya Institute of Technology and Sciences (Deemed-to-be University), Karunya Nagar, Coimbatore, 641 114, India.
Rajesh KannanDepartment of Microbiology, Bharathidasan Univeristy, Tiruchirappalli, 620 024, India.
C SelvarajComputer Aided Drug Design and Molecular Modeling Lab, Department of Bioinformatics, Science Block, Alagappa University, Karaikudi, 630004, Tamil Nadu, India.
S VishnuPriyaDepartment of Medical Neurobiology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, 91120, Israel.
G SelvarajCentre for Interdisciplinary Sciences-Computational Life Sciences, College of Food Science and Technology, Henan University of Technology, Zhengzhou, China.
S K SinghComputer Aided Drug Design and Molecular Modeling Lab, Department of Bioinformatics, Science Block, Alagappa University, Karaikudi, 630004, Tamil Nadu, India.
R NandhakumarDepartment of Applied Chemistry, Karunya Institute of Technology and Sciences (Deemed-to-be University), Karunya Nagar, Coimbatore, 641 114, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quinoline and imidazole derivatives have been playing a significant role in functional bioactivities and were potentially used as antibacterial, antifungal, anticancer, and anti-inflammatory drugs. Owing to the limitation of drug resistance, herein we synthesized thio-, chloro-, and hydroxyl-functionalized various imidazoquinolines by molecular hybridization approach. All the imidazoquinoline derivatives were examined for their antibacterial activity against selected bacterial pathogens by the agar well diffusion method. In addition, the anti-oxidant efficacy of imidazoquinolines was also tested using ferric reducing antioxidant power (FRAP). Among them, electron-withdrawing (-Cl) substituent containing imidazoquinoline

Indexed as

2-Chloro-3-formylquinolinesAntibacterialAntioxidantChloro-imidazoquinolinesHydroxy-imidazoquinolinesMolecular dockingMultidrug-resistantThio-imidazoquinolines

Identifiers

PMID34286142
PMCPMC8273425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.